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Background: Relationships between clinical outcomes and novel respiratory pathogens such as Trichosporon are not well understood. 
Methods: Respiratory cultures from CF patients were screened for novel pathogens Trichosporon and Chryseobacterium as well as other pathogens 
over 28 months. Relationships between microbiologic and clinical data were assessed using univariate and multivariate methods.
Results: Of 4934 respiratory cultures from 474 CF patients, 37 cultures from 10 patients were Trichosporon positive. Patients with positive 
Trichosproron cultures had a greater decline in FEV1 over time (−3.9%/year vs. -1.3%/year, p b 0.05), whereas Chryseobacterium did not influence 
lung function. These findings were confirmed in multivariate analyses that included age, gender, and other common pathogens as confounders. 
Treatment of Trichosporon infected patients was associated with improved lung function.
Conclusions: Trichosporon can be recovered from a small but clinically meaningful fraction of CF patients. The presence of Trichosporon, but not 
Chryseobacterium, is associated with greater declines in lung function.Keywords: Chryseobacterium; lung function1. Introduction
Cystic fibrosis is characterized by persistent infection with a
variety of respiratory pathogens, with Pseudomonas aeruginosa
and Staphylococcus aureus the most common. The contributions
of these and many other pathogens to CF lung disease have been
relatively well defined through epidemiological studies that
examine relationships between respiratory infection and clinicaloutcomes, most often lung function. For example, multiple studies
have demonstrated lung function declines more rapidly in CF
patients infected with Pseudomonas aeruginosa, Achromobacter
species, and Burkholderia cepacia complex. While not definitive,
such associations are generally used to identify the pathogens that
should be more aggressively targeted.
Over the past several years, several potential novel pathogens
have been recovered with greater frequency from CF respiratory
secretions. One such potential pathogen is Trichosporon, a soil
fungus that can be an opportunistic pathogen [1]. Trichosporon
species are generally refractory to treatment with amphotericin and
the echinocandins, and strains have been reported with reduced
susceptibility to azoles as well [1,2]. These resistances raise
the possibility that aggressive anti-fungal treatment of allergic
bronchopulmonary disease due to Aspergillus and Scedosporium
may be responsible for the emergence of this organism [3]. Over
the past decade, several case studies suggest that Trichosporon can
be recovered from culture of CF respiratory secretions [4] andmay
be associated with clinical deterioration in CF patients [5–7].
To better understand the potential pathogenicity
Trichosporon, we performed a prospective evaluation of
respiratory infection with Trichosporon species within all CF
patients in our center over 28 month period. Associations to
clinical outcome measures including percent predicted FEV1,
FEV1 decline over time, and nutritional status were then
examined using univariate and multivariate analyses to
establish links between infection and disease. As a control, we
performed a similar analysis with another potential novel
pathogen Chryseobacterium, a glucose non-fermenting gram
negative bacillus that was first identified in CF respiratory
cultures in 2002 [8], with subsequent case studies suggesting that
it may be a respiratory pathogen in CF [9,10]. Our goal was to
provide the comparative studies needed to define associations
between these pathogens and clinical outcomes.Table 1
CF Patient Demographics
n= 474
Age (years) 15.6 (IQR 7-24.2)
Gender (% male) 48.8%
Initial FEV1 (% predicted) 75 (IQR 51-93)
# Cultures 10 (IQR 7-13)2. Methods
2.1. Microbiological and clinical data
All respiratory samples fromCF patients at our institution were
prospectively screened on routine CF cultures for the presence of
Trichosporon and Chryseobacterium species as well as other CF
respiratory pathogens over a 28 month period (January 2009 –
April 2011). Routine CF culture was performed by inoculation of
respiratory samples onto chocolate agar, Columbia CNA agar
with 5% sheep blood, MacConkey agar, mannitol salt agar and
Burkholderia cepacia selective agar. Cultures were examined
daily for 4 days. Gram-negative glucose non-fermenters includ-
ing Chryseobacterium were identified using the VITEK 2 GN
panel (bioMérieux, Durham, NC). Yeast-like organisms that were
present in pure or predominant amount or had at least a confluent
growth at the primary zone of inoculation were identified. During
the study period, Trichosporon was identified by the colony and
Gram stain morphologies and was reported as Trichosporon
species [11]. The waxy, heaped and often wrinkled colonies with
or without a mycelial fringe, and presents of arthroconidia, true
hyphae, pseudohyphae and blastoconidia were considered to be
indicative of Trichosporon species. Archived isolates that were
available from a subset of patients were identified by sequencing
of the internal transcribed spacer (ITS) region and the D1/D2
region of the 28S ribosomal subunit, as described previously [12]
and were compared with sequences in NCBI BLASTN database.
Clinical patient data was abstracted from the Port CF database.
Patients with solid organ transplant during or prior to the study
period were excluded from analysis. Lung function was recorded
as percent predicted FEV1, and values obtained at less than
6 years of age were excluded as being potentially unreliable.
Change in lung function over time was defined as the slope by
linear regression of all available values. Change over time was not
calculated for patients with fewer than three lung function values
or less than three months of data available. This study was
approved by the UNC IRB (14–3272).2.2. Statistical analysis
Relationships between microbiologic and clinical data were
assessed using univariate methods, with Student's T-test or Mann–
Whitney based on the normality of the datasets. Multivariate
methods were performed using generalized linear mixed effects
models with random intercepts, which controlled for confounders
and presence of repeated measures. The normality and equal
variance assumption of the responses in the linear regression
model was carefully checked using adjusted residuals, and no
clear violation of the statistical assumptions was found. Analyses
were performed in GraphPad Prism v5.0 (La Jolla, CA) or SAS
version 9.2 (SAS, Cary, NC).
3. Results
A total of 4934 respiratory cultures from 474 individual
CF patients were included in the analysis, with an average of
10 cultures per patient over the 28 month study period (range
3–40, Table 1). As expected, S. aureus and P. aeruginosa
species were the most common pathogens, present on at
least one culture over the study period in 86% and 85% of
patients, respectively. Of the remaining pathogens identified
in N1% of cultures, all were relatively well described in the
CF literature (N30 references on PubMed) with the exception of
Trichosporon and Chryseobacterium species (b10 references for
each).
Trichosporon species were identified in 37 cultures (0.75%
of all cultures) from 10 individual patients (2.1% of all
patients). Six of the 10 patients had evidence of chronic
infection, with three or more Trichosporon positive cultures.
Eight of the 10 patients had received inhaled antibiotics within
the past six months, and two had a history of itraconazole treatment
for allergic bronchopulmonary aspergillosis. Archived isolates
from 7 patients, including 4 of those with chronic infection, were
viable for species identification by sequencing of the ITS and D1/
D2 regions. All were identified as T. mycotoxinivorans.
Several common CF pathogens were recovered in similar
rates in Trichosporon positive and negative patients, including
Pseudomonas (90% in positive, 84% in negative), Staphylococcus
(90% vs. 86%), and other molds (60% vs. 51%). Non-
pseudomonal gram negative rods, including Achromobacter,
Burkholderia, Ralstonia, and Stenotrophomonas species, were
recovered at higher rates in Trichosporon positive patients (80%
vs. 45%, p b 0.05), and there was a trend towards higher rates
of oxacillin resistant Staphylococcus aureus (ORSA) (70% vs.
43.1%, p = 0.11).
Patients positive for Trichosporon had a trend towards older
age (median 20.7 years, IQR 15.5-32.4 vs. median 15.5 years,
A B
C DIQR 6.8-24.2, p = 0.051, Fig. 1A) and had more respiratory
cultures obtained (median 11, IQR 10-22 vs. median 10, IQR
7-13, p b 0.03, Fig. 1B) than those who were Trichosporon
negative. In the subset of patients that could perform spirometry
(n = 10 Trichosporon positive, 340 Trichosporon negative),
univariate analyses revealed that Trichosporon positive patients
exhibited a trend towards lower initial percent predicted
FEV1 (median 55%, IQR 31.5-82.75% vs. median 76%, IQR
52-93%, p = 0.064, Fig. 1C) and had a significantly greater
decline in percent predicted FEV1 over time (median − 3.9%/
year, IQR −11.2 to −0.8%/year vs. median − 1.3%/year, IQR
−5.0 to −2.1%/year, p b 0.05, Fig. 1D).
Chryseobacterium species were identified in 34 cultures
(0.69%) from 29 individual patients (6.1%). No patient had
chronic infection (3 or more cultures) with Chryseobacterium,
significantly different from the relative high rate of chronic
infection observed with Trichosporon (p b 0.01). Patients with
Chryseobacterium infection were younger than those without
infection (median 12.6, IQR 2.3-20.5 years vs. median 16.0,
IQR 7.4-24.5 years, p b 0.05, Fig. 2A), and they also had
slightly more respiratory cultures obtained (median 11, IQR
8-16 vs. median 10, IQR 7-13, p b 0.05, Fig. 2B). In the subset
with spirometry data available (n = 17 Chryseobacterium
positive, 333 Chryseobacterium negative), initial percentA B
C D
Fig. 1. Clinical characteristics of CF patients with Trichosporon infection. In
univariate analyses, CF patients with at least one Trichosporon positive culture
had A) a trend towards older age (p = 0.051), B) more cultures obtained
(p b 0.03), C) a trend towards lower initial percent predicted FEV1 (p = 0.06),
and D) an increased rate of decline in percent predicted FEV1 over time
(p b 0.04) compared to patients with no Trichosporon positive cultures.
Fig. 2. Clinical characteristics of CF patients with Chryseobacterium infection.
In univariate analyses, CF patients with at least one Chryseobacterium positive
culture were A) younger (p b 0.05), B) had more cultures obtained (p b 0.05),
C) had no significant difference in initial predicted FEV1 (p = 0.14), and had
D) no difference in percent predicted FEV1 over time (p = 0.49) compared to
patients with no Chryseobacterium positive cultures.predicted FEV1 was similar in Chryseobacterium positive vs.
negative patients (median 84%, IQR 72-92.5% vs. median 73%,
IQR 50-93%, p = 0.19, Fig. 2C) as was decline in percent
predicted FEV1 over time (median − 1.9%/year, IQR −5.9 to −
0.8%/year vs. median − 1.5%/year, IQR −4.9 to 1.8%/year,
p = 0.49, Fig. 2D). Of note, no patients had positive cultures for
both Trichosporon and Chryseobacterium over the time frame of
the study.
To better assess clinical outcomes associated with these
organisms, multivariate analyses were performed including
Trichosporon or Chryseobacterium respiratory culture status as
well as the culture status of common CF pathogens (S. aureus,
ORSA, P. aeruginosa, and non pseudomonal glucose non-
fermenters) plus age, gender, and nutritional status as potential
confounders. For both organisms, multivariate models were
constructed for initial percent predicted FEV1 as well as change
in FEV1 over time (Tables 2 and 3). For initial FEV1, age,
nutritional failure, and infection with either P. aeruginosa or
non-pseudomonal glucose non-fermenters were all negatively
associated. Trichosporon infection was not associated with initial
percent predicted FEV1 but was strongly correlated with change in
FEV1 over time (β = −0.16, p = 0.003) in multivariate analyses.
Initial FEV1 was the only other variable predictive of changes in
Table 2
Multivariate analysis of Trichosporon infection.
Initial FEV1 ΔFEV1 over time
Variable β p-value β p-value
FEV1, % predicted - - −0.161 0.015
Age −0.486 0.000 −0.114 0.063
Nutritional Failure −0.323 0.000 0.067 0.229
Staphylococcus sps 0.054 0.215 0.083 0.133
ORSA −0.080 0.070 −0.097 0.087
Pseudomonas sps. −0.117 0.005 −0.017 0.749
Non-Pseud GNR −0.102 0.012 −0.066 0.202
Trichosporon −0.039 0.336 −0.155 0.003
Fig. 3. Antifungal treatment in patients with Trichosporon infection. In patients
with Trichosporon respiratory infection, improvements in percent predicted FEV1
were observed three months after initiation of antifungal treatment. * = p b 0.05.FEV1 over time.In contrast, Chryseobacterium culture status was
not associated with the initial percent predicted FEV1 or with
change in FEV1 over time in multivariate analysis. Interestingly,
there was a trend (β = 0.078, p = 0.051) towards improved
percent predicted FEV1 in patients with Chryseobacterium
respiratory infection.
Among the Trichosporon infected patients, we identified
six who underwent antifungal treatment directed against this
pathogen and had lung function values obtained within a week
of treatment initiation. Initial treatment regimens consisted of
itraconazole (200–400 mg twice daily), voriconazole (200–
400 mg twice daily), or fluconazole (400 mg once daily) and
lasted an average of 97 ± 33 days. Lung function values obtained
approximately three months after start of treatment (average
102 ± 23 days) were significantly improved relative to initial
values (Fig. 3).
4. Discussion
Both Trichosporon and Chryseobacterium species were
recovered from respiratory cultures in a small but meaningful
fraction of patients with CF. However, clinical features
associated with infection were very different for the two
organisms. Trichosporon respiratory infection was more often
chronic and tended to occur in older, sicker individuals. In
contrast, Chryseobacterium was not associated with chronic
infection in this study and was more often isolated from
younger patients a trend towards better lung function. More
importantly, Trichosporon, but not Chryseobacterium, was
associated with greater decline in lung function over time in
both univariate and multivariate analyses controlling for
other markers of disease severity. While this association doesTable 3
Multivariate analysis of Chryseobacterium infection.
Initial FEV1 ΔFEV1 over time
Variable β p-value β p-value
FEV1, % predicted - - −0.149 0.027
Age −0.488 0.000 −0.118 0.056
Nutritional Failure −0.325 0.000 0.065 0.250
Staphylococcus sps 0.051 0.233 0.085 0.128
ORSA −0.086 0.050 −0.107 0.062
Pseudomonas sps. −0.113 0.007 −0.013 0.808
Non-Pseud GNR −0.110 0.006 −0.079 0.131
Chryseobacterium 0.078 0.051 −0.020 0.706not necessarily indicate causation, the results suggest that
Trichosporon infection may lead to progressive lung damage.
The relationship between Trichosporon respiratory infection
and deterioration in lung function is consistent with previous
case series. Kroner et al. reported “greater decline in FEV1 than
expected” in 4 of 8 CF patients infected with Trichosporon,
with some patients improving after initiation of antifungal
therapy [6], and similar anecdotal relationships have been
described in other reports [4,6]. However, this is the first study
to systematically examine clinical outcome measures in CF
patients with Trichosporon respiratory infection relative to
those that did not culture this pathogen.
These data suggest that treatment of Trichosporon respiratory
infection may be indicated in CF in the setting of clinical decline.
Most Trichosporon species are susceptible to triazole antifungals,
though resistance to other antifungal classes has been reported
[1,2]. Our evaluation of patients treated with these agents for
Trichosporon demonstratedmodest improvements in lung function
after antifungal therapy, but these retrospective data should be
interpreted very cautiously. Most patients were being simulta-
neously treated with other antibiotics targeted towards other
respiratory pathogens, and it is impossible in this retrospective
study to determine which therapies were most associated with
clinical improvement. Nevertheless, these results suggest that
controlled trials of antifungal therapy are indicated to determine the
role and utility of antifungal therapy for affected patients. Although
concern has been raised that previous treatment with azole
antifungals might contribute to emergence of Trichosporon
respiratory infection [3], we found a history of previous azole
treatment in only two of the ten Trichosporon infected patients,
which is insufficient to draw any conclusions regarding a potential
association.
Although T. ashaii, T. mucoides, T. asteroides, and T. inkin
account for the vast majority of invasive human Trichosporon
infections [13,14], our available isolates were all identified as
T. mycotoxinivorans. Previous case reports and case series have
shown that the clinical spectrum of T. mycotoxinivorans ranges
from chronic infections to fulminant diseases, and this species has
been recognized as a potential pathogen in CF patients [4–7].
However, pathogenesis underlying the relationship between
T. mycotoxinvorans infection and patients with CF has not been
studied.
The lack of relationship between Chryseobacterium respi-
ratory infection and clinical outcome measures is somewhat
surprising given previous reports suggesting pathogenic status,
though objective measures of decline have not been reported
[9,10]. The fact that patients with Chryseobacterium positive
cultures actually had a trend towards higher lung function
values suggests that this organism is a less virulent, somewhat
sporadic pathogen. However, we cannot rule out the possibility
thatChryseobacterium respiratory infection could be problematic
in a subset of individuals.
In summary, our cohort analysis suggest that Trichosporon,
but not Chyrseobacterium respiratory infection is associated with
decline in lung function over time. This data should help guide
treatment decisions for CF patients infected with these pathogens.
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